Hemogenyx Pharmaceuticals Plc

HOPHF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$5,625-$6,696-$3,987-$5,108
Dep. & Amort.$639$646$195$126
Deferred Tax$0$0$4-$18
Stock-Based Comp.$344$243$18$153
Change in WC$256-$834$243$101
Other Non-Cash$246$536$617$2,118
Operating Cash Flow-$4,140-$6,106-$2,911-$2,627
Investing Activities
PP&E Inv.-$13-$117-$429-$818
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0-$2-$139
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$12$85$11$18
Investing Cash Flow-$2-$32-$420-$939
Financing Activities
Debt Repay.-$635$0$0$8,817
Stock Issued$4,645$5,088$0$12,000
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$932-$639-$110-$39
Financing Cash Flow$3,077$4,449-$110$8,778
Forex Effect-$24$403-$876-$183
Net Chg. in Cash-$1,088-$1,285-$4,308$5,029
Supplemental Information
Beg. Cash$1,248$2,533$6,841$1,812
End Cash$159$1,248$2,533$6,841
Free Cash Flow-$4,153-$6,223-$3,340-$3,445